Stockwatch: The Victimization Of Big Biotech
Early Success In Biotech Raises An Almost Impossible Bar
Executive Summary
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
You may also be interested in...
Roche Mounts NMOSD Challenge To Alexion’s Soliris
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.
Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
Stock Watch: Contrasting Novartis And J&J Stock Movements Defy Explanation
Among equity investors there is concern about the impact of macroeconomic headwinds on second-quarter earnings. The first two big life sciences companies’ reports did nothing to alleviate those concerns.